Skinobac ointment is indicated for the topical treatment of impetigo due to: Staphylococcus aureus and Streptococcus pyogenes.
Dosage & Administration
A small amount of Skinobac ointment should be applied to the affected area three times daily. The area treated may be covered with gauze dressing if desired. Patients not showing a clinical response within 3 to 5 days should be re-evaluated.
Mupirocin ointment is not for ophthalmic or intra-nasal use. If a reaction suggesting sensitivity or chemical irritation should occur with the use of Mupirocin ointment, treatment should be discontinued and appropriate alternative therapy for the infection instituted. As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. When Mupirocin is used on the face care should be taken to avoid the eyes. Polyethylene Glycol can be absorbed from open wounds and damaged skin and is secreted by the kidneys. In common with other polyethylene glycol-based ointments, Mupirocin ointment should not be used in conditions where absorption of large quantities of polyethylene glycol is possible, especially if there is evidence of moderate or severe renal impairment.
Use in Specific Population
Use in Pregnancy: The drug is classified in Pregnancy Category B. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Use in Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Mupirocin is used to a nursing woman.
Pediatric Use: The safety and effectiveness of Mupirocin have been established in the age range of 2 months to 16 years. Use of the ointment in these age groups is supported by evidence from adequate and well-controlled studies of Mupirocin in impetigo in pediatric patients.